← Back to Clinical Trials
Recruiting Phase 2 NCT05045950

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique

Trial Parameters

Condition Brain Metastases
Sponsor Medical College of Wisconsin
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 53
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2021-11-17
Completion 2028-05
Interventions
Memantine -Twice Daily or Extended ReleaseWBRT utilizing the PRDR technique

Brief Summary

Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.

Eligibility Criteria

Inclusion Criteria: 1. Age ≥18 years at diagnosis of brain metastases. 2. Eastern Cooperative Oncology Group (ECOG) Performance Score of \<2. 3. Participants must have a biopsy-proven solid malignancy (histologic proof or unequivocal cytologic proof solid tumor malignancy from either the primary or any metastatic site) with intracranial lesions radiographically consistent with or pathologically proven to be brain metastases. 4. Patients who have undergone prior systemic therapy are eligible. 5. Life expectancy from extracranial disease greater than six months. 6. Patients with measurable brain metastasis. 7. Patients may have had prior therapy for brain metastasis, including stereotactic radiosurgery (SRS)and surgical resection. Patients must have completed prior therapy by at least 7 days prior to study enrollment for SRS and at least 14 days for surgical resection 8. If an open biopsy is performed, the patient must be at least one-week post-biopsy. This requirement is not necessary f

Related Trials